The Cigna Group 8-K
EarningsGuidance raised
Large client renewals and investment squeezed Pharmacy Benefit Services profit; FY2026 adjusted EPS guidance rose to at least $30.60
Filed 2026-11-05 06:15 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q3 2026 results and raised FY2026 outlook. Shareholders’ net income declined as the prior-year quarter included an after-tax gain on a business sale; growth in adjusted income from operations per share, Cigna’s measure excluding investment results, acquired-intangible amortization and special items, slowed to +1.9% Y/Y from +8.1% in Q2.
FY2026 adjusted income from operations per share guidance rose to at least $30.60 from at least $30.45; the 9M result was $23.55.
Developments
- At Investor Day, Cigna introduced its “Lead to One” vision, set targets of 10%-14% adjusted EPS CAGR and ≈$50B in cumulative operating cash flow through 2030, and announced “Accelerate to One,” a multi-year $3B modernization and productivity initiative.
- Customer relationships totaled 177.6M at 9/30/2026, down 6% from year-end 2025, as pharmacy customers fell 5% to 117.7M and behavioral customers fell 19% to 23.0M. Medical customers rose 2% to 18.5M, with growth in Middle and Select markets partly offset by lower National Accounts membership; the behavioral decline followed a government contract termination and had minimal revenue and adjusted-income impact.
Results with guidance
| Metric | Q3 2026 actual | 9M 2026 | FY2026 guide |
|---|---|---|---|
| Adjusted Income from Operations, per share (non-GAAP) | $7.98+1.9% Y/Y, +2.6% Q/Q | $23.55+8.2% Y/Y | at least $30.60raised from at least $30.45 |
| Evernorth Health Services Evernorth Adjusted Income from Operations, Pre-Tax | — | — | at least $6.9Breaffirmed from at least $6.9B |
| Cigna Healthcare Adjusted Income from Operations, Pre-Tax | — | — | at least $4.6Braised from at least $4.55B |
Results without guidance
| Metric | Q3 2026 | Change | 9M 2026 |
|---|---|---|---|
| Revenue | $73.7B | +2.8% Q/Q | $214B |
| Net income | $1.44B | -23% Y/Y, -13% Q/Q | $4.76B+0.7% Y/Y |
| Diluted EPS | $5.47 | -22% Y/Y, -13% Q/Q | $18.02+2.9% Y/Y |
| Diluted shares | 264M | -1.4% Y/Y, -0.1% Q/Q | 264M-2.1% Y/Y |
What moved the numbers
- Evernorth Health Services adjusted revenues, which exclude special items and specified equity-method investment results, rose 6% Y/Y to $63.8B, while adjusted income from operations, pre-tax, fell 4% to $1.83B. Pharmacy Benefit Services revenue rose 9% on drug mix, but operating income fell 22% to $765M amid large client renewals and strategic investment. Specialty and Care Services revenue rose 1% and operating income rose 15% to $1.06B, supported by specialty distribution growth and higher biosimilar and specialty generic adoption.
- Cigna Healthcare adjusted revenues rose 9% Y/Y to $11.7B, primarily on premium rate increases, and adjusted income from operations, pre-tax, rose 15% to $1.19B, reflecting higher net investment income and improved operating efficiency. Its medical care ratio was 85.0% vs 84.8% a year earlier; net medical costs payable were $4.86B at 9/30/2026.
- The GAAP/non-GAAP earnings difference included $449M of after-tax amortization of acquired intangible assets ($1.71 per diluted share) excluded from adjusted income. The prior-year quarter also included a $241M after-tax gain on sale of businesses.
- Cigna repurchased 1.8M shares for ≈$500M YTD through 11/04/2026. Its debt-to-capitalization ratio was 41.8% at 9/30/2026, vs 44.9% a year earlier and 43.0% at 12/31/2025.
Other guidance (3)
| Metric | Period | Guidance |
|---|---|---|
| adjusted EPS CAGR (non-GAAP) | through 2030 | 10%-14% growth Y/Y |
| cumulative operating cash flow | through 2030 | $50B |
| Accelerate to One modernization and productivity initiative | multi-year | $3B |
Figures extracted from the filings and checked against their text; changes and verdicts computed from them.
The summary is written by an AI model reading the filing.
Model 005 · prompt v189 · 2026-11-05 20:58:45Z